



May 15, 2018

Dear SMA Community,

Following the announcement last month, we wanted to let you know that AveXis (the gene therapy company developing a new approach to treat SMA known as AVXS-101) is officially a Novartis company.

AveXis remains steadfastly dedicated to the SMA community, and we are excited about the promise of the future as a part of this organization. As a Novartis company, we hope to accelerate our mission of bringing AVXS-101 to people with SMA as quickly and safely as possible.

If you have any questions about the acquisition or our programs in SMA, please continue to contact us at [medinfo@avexis.com](mailto:medinfo@avexis.com).

Sincerely,

The AveXis Team